Table 1.

Clinicopathologic features and analysis of PGAM1 and pS6 expression in tumor tissues of NSCLC patients

Characteristics	Total cases	PGAM1 staining		P value	pS6 staining		P value
		Low level (%)	High level (%)		Low level (%)	High level (%)
Age (years)
≤60	107	55 (51.4)	52 (48.6)	0.677	68 (63.5)	39 (35.4)	0.152
>60	120	65 (54.2)	55 (45.8)		65 (54.2)	55 (45.8)
Gender
Male	149	84 (56.4)	65 (43.6)	0.143	93 (62.4)	56 (37.6)	0.106
Female	78	36 (46.2)	42 (53.8)		40 (51.3)	38 (48.7)
Smoking status
Non smoker	77	34 (44.2)	43 (55.8)	0.060	39 (50.6)	38 (49.4)	0.082
Smoker	150	86 (57.3)	64 (42.7)		94 (62.7)	56 (37.3)
Histology
ADC	71	34 (47.9)	37 (52.1)	0.061	35 (49.3)	36 (50.7)	0.132
SCC	99	61 (61.6)	38 (38.4)		64 (64.6)	35 (35.4)
LCLC	57	25 (43.9)	32 (56.1)		34 (59.6)	23 (40.4)
Pathological T category
pT1/pT2	182	102 (56.0)	80 (44.0)	0.054	110 (60.4)	72 (39.6)	0.255
pT3/pT4	45	18 (40.0)	27 (60.0)		23 (51.1)	22 (48.9)
Lymph node metastasis
Absent	122	72(59.0)	50 (41.0)	0.045	76 (62.3)	46 (37.7)	0.222
Present	105	48 (45.7)	57 (54.3)		57 (54.3)	48 (45.7)
Distant metastasis
Absent	205	117 (57.1)	88 (42.9)	<0.001	128 (62.4)	77 (37.6)	<0.001
Present	22	3 (13.6)	19 (86.4)		5 (22.7)	17 (77.3)
Clinical stage
Stage I/II	127	80 (63.5)	47 (36.5)	0.001	81 (63.8)	46 (36.2)	0.074
Stage III/IV	100	40 (40.0)	60 (60.0)		52 (52.0)	48 (48.0)
pS6 expression
Low level	133	102 (76.7)	31 (23.3)	<0.001
High level	94	18 (19.1)	76 (80.9)

χ² Test. ADC adenocarcinoma, NSCLC non-small cell lung cancer, PGAM1 phosphoglyceric acid mutase-1, pS6 protein S6, SCC squamous carcinoma, LCLC large-cell lung cancer